ArticleCNS neuroscience & therapeutics2026
Vorinostat Mitigates Early Brain Injury Following Subarachnoid Hemorrhage Through Modulation of the C3aR1/TGF-β/Smad Pathway.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExcessive microglial activation after subarachnoid hemorrhage (SAH) contributes to early brain injury (EBI) and poor clinical outcomes. This study explores the role of complement C3a receptor 1 (C3aR1) in microglial activation after SAH and evaluates Vorinostat as a potential therapeutic agent.
methodsDifferentially expressed genes were identified from GEO datasets (GSE36791, GSE73378), followed by WGCNA and machine learning to pinpoint key SAH-related genes. Molecular docking and molecular dynamics simulation identified Vorinostat as a potential C3aR1-targeting compound. Functional studies were conducted using C3aR1 knockout mice and BV2 microglial cells. Neurological outcomes were assessed through Garcia score, rotarod, and pole tests. Histological staining and immunofluorescence evaluated neuronal injury and microglial activation. ELISA was used to measure plasma C3aR1 and inflammatory markers in SAH patients and correlate them with 6-month modified Rankin Scale (mRS) scores.
resultsC3aR1 was identified as a key SAH-related gene and was significantly upregulated after SAH. C3aR1 deficiency alleviated brain edema, neuronal apoptosis, neuroinflammation, and neurological dysfunction in SAH mice. Transcriptomic and functional analyses demonstrated that these protective effects were mediated, at least in part, through activation of the TGF-β/Smad signaling pathway. In vitro, C3aR1 knockdown suppressed microglial proliferation, migration, phagocytosis, and inflammatory responses, while reducing oxidative stress in co-cultured neurons; opposite effects were observed following C3aR1 overexpression. Vorinostat exhibited strong binding affinity to C3aR1, reduced C3aR1 protein expression, activated TGF-β/Smad signaling, and attenuated EBI after SAH. Clinically, plasma C3aR1 levels were significantly elevated in SAH patients, correlated with inflammatory cytokines and 6-month modified Rankin Scale scores, and independently predicted poor functional outcomes.
conclusionC3aR1 promotes microglial overactivation and neuronal injury after SAH, partly via suppression of TGF-β signaling. Vorinostat attenuates EBI and is associated with reduced C3aR1 expression. Plasma C3aR1 may serve as a prognostic biomarker in SAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.